<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923921</url>
  </required_header>
  <id_info>
    <org_study_id>AM0010-301</org_study_id>
    <nct_id>NCT02923921</nct_id>
  </id_info>
  <brief_title>Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer</brief_title>
  <official_title>Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARMO BioSciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of AM0010 in combination with FOLFOX versus FOLFOX alone in patients
      with metastatic pancreatic cancer as measured by overall survival
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, randomized, Phase 3 study designed to compare the
      efficacy and safety of AM0010 in combination with FOLFOX versus FOLFOX alone in patients
      with metastatic adenocarcinoma of the pancreas who have progressed on one prior gemcitabine
      containing regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months after the last patient randomized</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>36 months after the last patient randomized</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>36 months after the last patient randomized</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">566</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (5 μg/kg) dosed on Days 1-5 and Days 8-12 SQ plus FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles or until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles or until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AM0010</intervention_name>
    <description>AM0010 plus FOLFOX</description>
    <arm_group_label>ARM 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>FOLFOX Alone</description>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 2</arm_group_label>
    <other_name>oxaliplatin</other_name>
    <other_name>5-FU</other_name>
    <other_name>leucovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The presence of metastatic pancreatic adenocarcinoma

          2. Measurable disease per RECIST v.1.1

          3. Patient must have documented tumor progression during or following a gemcitabine
             containing regimen to treat metastatic disease as established by CT or MRI scan

          4. Eastern Cooperative Oncology Group Performance Status of 0 - 1

          5. Patient must have completed prior chemotherapy at least 2 weeks (washout period)
             prior to randomization and recovered from toxicity to Grade 1 or baseline

          6. Patients must not have received previous radiation therapy or investigational therapy
             for the treatment of advanced metastatic disease.

          7. Patients having received cytotoxic doses of gemcitabine or any other chemotherapy in
             the adjuvant setting are not eligible for this study

          8. No peripheral neuropathy

          9. No known history of dihydropyrimidine dehydrogenase deficiency

        Exclusion Criteria:

          1. Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non- adenocarcinoma
             (i.e., lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or
             cystadenocarcinoma

          2. Patient on Coumadin and not willing to change to LMWH or oral Factor II or Xa
             inhibitor with half-life of less than 24 hours.

          3. Patient has received prior treatment with AM0010 or fluoropyrimidine/platinum
             containing regimen

          4. Patients who were intolerant of a gemcitabine containing regimen.

          5. History of positivity for human immunodeficiency virus

          6. Chronic active or active viral hepatitis A, B, or C infection

          7. Clinically significant bleeding within two weeks prior to randomization (e.g.,
             gastrointestinal (GI) bleeding, intracranial hemorrhage)

          8. Pregnant or lactating women

          9. Patients with a history of immune-mediated neurological disorders such as multiple
             sclerosis, Guillain-Barré or inflammatory CNS/PNS disorders

         10. Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks

         11. Major surgery, defined as any surgical procedure that involves general anesthesia and
             a significant incision (i.e., larger than what is required for placement of central
             venous access, percutaneous feeding tube, or biopsy),within 28 days prior to
             randomization or anticipated surgery during the study period

         12. Prior history of receiving immune modulators including, but not limited to,
             anti-CTLA4, anti-PD1, anti-PD-L1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>650-771-9325</phone>
    <email>AM0010-301@armobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany White</last_name>
      <phone>205-263-9746</phone>
    </contact>
    <investigator>
      <last_name>Shaily Lakhanpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genet Sisay</last_name>
      <phone>714-992-3000</phone>
      <phone_ext>4511</phone_ext>
    </contact>
    <investigator>
      <last_name>David J Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Gonzales</last_name>
      <phone>904-202-7319</phone>
    </contact>
    <investigator>
      <last_name>Robert Zaiden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mose</last_name>
      <phone>217-876-4765</phone>
    </contact>
    <investigator>
      <last_name>James L. Wade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Zutt</last_name>
      <phone>502-629-3589</phone>
    </contact>
    <investigator>
      <last_name>John Hamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evie Key</last_name>
      <phone>225-761-3951</phone>
    </contact>
    <investigator>
      <last_name>Gerald P Miletello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay St. Louis</last_name>
      <phone>207-396-8587</phone>
    </contact>
    <investigator>
      <last_name>Matthew C Dugan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cipriano</last_name>
      <phone>240-482-0556</phone>
    </contact>
    <investigator>
      <last_name>Ralph V. Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Gregoire</last_name>
      <phone>508-865-2024</phone>
    </contact>
    <investigator>
      <last_name>Venu Bathini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Oncology Specialists</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Carr</last_name>
      <phone>336-718-8481</phone>
    </contact>
    <investigator>
      <last_name>Heather Shearer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Curry</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>207</phone_ext>
    </contact>
    <investigator>
      <last_name>Nashat Y. Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Marx</last_name>
      <phone>615-524-4161</phone>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Crews</last_name>
      <phone>804-288-7159</phone>
    </contact>
    <investigator>
      <last_name>Seaborn Wade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Chaudhry</last_name>
      <phone>509-462-2273</phone>
    </contact>
    <investigator>
      <last_name>Arvind Chaudhry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>September 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
